Evaluation of RNA data from the Aging, Dementia and TBI Study Consortium revealed that transcript levels of brevican correlate with AD parameters such as p-Tau or the Aβ ratio, whereas at the protein level total brevican immunoreactivity was unchanged in brain homogenates. The gene discussed is MAPT; the disease is Alzheimer disease.